RenovoRx, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for RNXT, updated each market day.
RNXT AI Sentiment
AI sees no strong directional signal for RenovoRx, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About RenovoRx, Inc. Common Stock
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Sector
Exchange
Market Cap
$44,079,567
Cap Tier
Employees
17
Headquarters
MOUNTAIN VIEW, CA
Listed Since
Aug. 26, 2021
Website
RNXT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
RNXT Volatility
RenovoRx, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
